Cancer Discov. 2020 May;10(5):630. doi: 10.1158/2159-8290.CD-NB2020-021. Epub 2020 Apr 1.
As the COVID-19 pandemic worsens, the clinical cancer community is grappling with how to continue providing access to experimental but potentially lifesaving therapies while keeping immunocompromised patients safe. To that end, cancer centers are making changes to their clinical trial programs, while pharmaceutical companies are deciding how-or whether-trials should continue.
随着 COVID-19 大流行的恶化,临床癌症领域正在努力寻找如何在确保免疫功能低下患者安全的同时,继续为他们提供有希望的实验性治疗方法。为此,癌症中心正在改变临床试验计划,而制药公司则在决定是否以及如何继续进行试验。